Bryant Chan, OD
Optometry · Los Altos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chan’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C34905 · Cancelled
Licence status: Cancelled · since 1973 · University of Texas Medical Branch at Galveston.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$0 in 2023
Medicaid paid $0 for 792 billed services this clinician did in 2023, up to 89 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| INTRM OPH EXAM NEW PATIENT | 56 | $0 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 14 | $0 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 499 | $0 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 13 | $0 |
| New patient visit (30+ min) | 30 | $0 |
| New patient visit (45+ min) | 180 | $0 |
| 2023 | 792 | 6 | 89 | $0 |
| 2022 | 1,249 | 5 | 121 | $0 |
See the largest Medicaid services in earlier years
2022
| INTRM OPH EXAM NEW PATIENT | 414 | $0 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 498 | $0 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 248 | $0 |
| New patient visit (30+ min) | 13 | $0 |
| New patient visit (45+ min) | 76 | $0 |
Drugs they prescribed that Part D paid
$41,620
Pharmacies billed $41,620 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 245) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
139 generic and 106 brand-name prescriptions · $41,620 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 21 | $14,149 | $674 |
| Xiidra | 13 | $8,742 | $672 |
| Cyclosporine | 13 | $6,189 | $476 |
| Brimonidine Tartrate-Timolol | 11 | $3,363 | $306 |
| Latanoprost | 124 | $1,081 | $9 |
See all 7 drugs
| Restasis | 21 | $14,149 | $674 |
| Xiidra | 13 | $8,742 | $672 |
| Cyclosporine | 13 | $6,189 | $476 |
| Brimonidine Tartrate-Timolol | 11 | $3,363 | $306 |
| Latanoprost | 124 | $1,081 | $9 |
| Dorzolamide-Timolol | 17 | $289 | $17 |
| Timolol Maleate | 17 | $170 | $10 |
Year by year
| 2024 | 245 | 80 | 0% (0) | 43% | $41,620 |
| 2023 | 1,906 | 483 | 0% (0) | 43% | $339,497 |
| 2022 | 1,635 | 512 | 0% (0) | 53% | $468,497 |
| 2021 | 134 | 83 | 0% (0) | 55% | $40,061 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Restasis | 126 | $128,027 | $1,016 |
| Xiidra | 81 | $65,594 | $810 |
| Lumigan | 70 | $30,521 | $436 |
| Cyclosporine | 57 | $26,647 | $467 |
| Latanoprost | 739 | $15,552 | $21 |
| Cequa | 18 | $10,890 | $605 |
| Azelastine | 216 | $9,367 | $43 |
| Vyzulta | 16 | $6,623 | $414 |
| Combigan | 24 | $5,646 | $235 |
| Brimonidine Tartrate-Timolol | 16 | $5,522 | $345 |
| Dorzolamide-Timolol | 141 | $5,350 | $38 |
| Timolol Maleate | 164 | $4,164 | $25 |
| Rhopressa | 12 | $3,989 | $332 |
| Travoprost | 18 | $3,713 | $206 |
| Dorzolamide | 56 | $1,936 | $35 |
| Brimonidine | 71 | $1,049 | $15 |
| Prednisolone Acetate | 15 | $497 | $33 |
2022: 14 drugs
| Restasis | 281 | $278,787 | $992 |
| Xiidra | 58 | $51,443 | $887 |
| Lumigan | 80 | $40,381 | $505 |
| Rhopressa | 31 | $15,212 | $491 |
| Latanoprost | 543 | $13,330 | $25 |
| Cequa | 19 | $10,686 | $562 |
| Cyclosporine | 19 | $9,771 | $514 |
| Travoprost | 29 | $5,922 | $204 |
| Dorzolamide-Timolol | 131 | $5,893 | $45 |
| Azelastine | 144 | $5,326 | $37 |
| Combigan | 12 | $5,214 | $435 |
| Timolol Maleate | 134 | $3,094 | $23 |
| Dorzolamide | 34 | $1,103 | $32 |
| Brimonidine | 31 | $835 | $27 |
2021: 4 drugs
| Restasis | 18 | $22,301 | $1,239 |
| Rhopressa | 14 | $5,619 | $401 |
| Latanoprost | 39 | $943 | $24 |
| Dorzolamide-Timolol | 12 | $732 | $61 |
Money from drug and device companies
$95 in 2025
| 2025 | 4 | 4 | None | $95 |
| 2024 | 3 | 3 | None | $69 |
| 2023 | 7 | 17 | None | $486 |
| 2022 | 4 | 19 | None | $526 |
| 2021 | 2 | 2 | None | $31 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Tryptyr | $27 | 1 payment
|
| Abbvie | Lumigan | $26 | 1 payment
|
| Thea Pharma | Iyuzeh | $23 | 1 payment
|
| Bausch & Lomb Americas | Xiidra | $19 | 1 payment
|
See all 4 published payments
| Alcon Vision | Meals · 2025-08-12 | Tryptyr | $27 |
| Thea Pharma | Meals · 2025-04-08 | Iyuzeh | $23 |
| Bausch & Lomb Americas | Meals · 2025-03-31 | Xiidra | $19 |
| Abbvie | Meals · 2025-03-12 | Lumigan | $26 |
See earlier years (2024, 2023, 2022, 2021)
2024: $69
| Harrow Eye | Vevye | $27 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $21 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $20 | 1 payment
|
2023: $486
| Novartis Pharmaceuticals | Xiidra | $142 | 8 payments
|
| Johnson & Johnson Surgical Vision | Amo Phaco Needle | $126 | 2 payments
|
| Dompe US | Oxervate | $68 | 1 payment
|
| Johnson & Johnson Vision Care | Acuvue | $51 | 2 payments
|
| Alcon Vision | Rocklatan | $44 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $33 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $22 | 1 payment
|
2022: $526
| Novartis Pharmaceuticals | Xiidra | $178 | 14 payments
|
| Abbvie | Vuity | $168 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $120 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $61 | 2 payments
|
2021: $31
| Sun Pharmaceutical Industries | Cequa | $17 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $14 | 1 payment
|
Professional record
- NPI
- 1154097608
- Licence
- CA 34905California C34905: Cancelled
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X); Federal specialty code 152WC0802X (152WC0802X)
- Mailing address
- 3400 Cottage Way, Ste G2 #19318, Sacramento, CA, 95825
- NPI first listed
- 2021-08-16
- NPI last updated
- 2025-05-22
- NPI record certified
- 2025-05-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 795 El Camino Real, Palo Alto, CA, 94301 · 301 Industrial Rd, San Carlos, CA, 94070